Difference between revisions of "DSCAM-AS1"
| (One intermediate revision by the same user not shown) | |||
| Line 9: | Line 9: | ||
===Chromosome=== | ===Chromosome=== | ||
21q22.2 | 21q22.2 | ||
| − | |||
| − | |||
===RefSeq(supplied by NCBI)=== | ===RefSeq(supplied by NCBI)=== | ||
NR_038896 | NR_038896 | ||
| − | |||
| − | |||
===Disease=== | ===Disease=== | ||
breast cancer | breast cancer | ||
| Line 36: | Line 32: | ||
==References== | ==References== | ||
<references> | <references> | ||
| − | <ref name="ref1"> | + | <ref name="ref1"> Niknafs, Y.S., et al., The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun, 2016. 7: p. 12791. |
</ref>(1) | </ref>(1) | ||
</references> | </references> | ||
Latest revision as of 08:33, 13 November 2017
Contents
Annotated Information
Approved Symbol
DSCAM-AS1 （DSCAM antisense RNA 1）
Characterization of DSCAM-AS1[1]
Physical and functional relationship of DSCAM-AS1 with hnRNPL[1]
Synonyms
M41
Chromosome
21q22.2
RefSeq(supplied by NCBI)
NR_038896
Disease
breast cancer
Characteristics
ER preferentially binds to the DSCAM-AS1 promoter in tumours with clinical aggression.[1]
Function
DSCAM-AS1 mediates tumour progression and tamoxifen resistance.[1] DSCAM-AS1 provides oestrogen-independent growth and a proliferative advantage when grown in oestrogen-deprived medium compared to normal serum.[1]
Regulation
hnRNPL is an interacting protein involved in the mechanism of DSCAM-AS1 action.[1]
Expression
DSCAM-AS1 expression is highly enriched in ER-positive tumours.[1]
Labs working on this lncRNA
- Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan 48109, USA
- Department of Cellular and Molecular Biology, University of Michigan, Ann Arbor, Michigan 48109, USA.
